{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'week 7 telephone call, if a stable dose is reached before then, the patient should continue taking that dose for the', 'remainder of the titration period and throughout maintenance dosing. If a patient experiences a \"clinically', 'significant\" adverse event that is attributed to the IMP, the investigator will determine if a dose reduction or', \"suspension is necessary. At the end of the titration period, the patient's dose will be established for the maintenance\", 'period. If a patient experiences an adverse event during the maintenance period and the investigator believes a dose', 'reduction in warranted, the dose may be reduced.', 'TEV-50717 tablets are available in the following dose strengths: 6, 9, 12, 15, and 18 mg, all of which are identical in', 'size, shape, and color (white). The IMP will be supplied in 40-count blister packs. The placebo tablets and', 'packaging will match those for TEV-50717.', 'IMP will be administered as follows:', 'IMP should be swallowed whole and taken with food. Tablets should be taken with food (eg, a snack)', 'and should not be taken on an empty stomach.', 'Dosing will be based on body weight and CYP2D6 impairment status at the baseline visit, as shown in', 'the tables below.', 'The starting dose is 6 mg in all patients. Daily doses will be administered twice daily, approximately', '8 to 10 hours apart during the day. A minimum of 6 hours should elapse between doses. If a patient', 'misses a dose, and it is within 6 hours of their next dose, the missed dose should be skipped.', 'After week 1, dose increases may not occur more frequently than every 5 days.', 'Dose reductions, if required, should be in increments of 6 mg. If more than 1 dose reduction is', 'required for an adverse event, the medical monitor must be notified.', 'During the titration period, the dose of IMP should be adjusted weekly according to the table below to', 'identify a dose level that optimally reduces tics and is well tolerated. Investigators will be blinded to', 'CYP status, with a dose cap for poor metabolizers prespecified by the IRT.', 'Maximum Daily Dose of IMP by Study Day and Weight Category at Baseline', 'Weight category', 'Study daya', '20 to <30 kg', '30 to <40 kg', '>40 kg', 'CYP', 'Not', 'Impaired', 'Not', 'Impaired', 'Not impaired', 'Impaired', 'impairment', 'impaired', 'impaired', 'status', 'Day 1-7', '6 mg', '6 mg', '6 mg', '6 mg', '6 mg (Days 1', '6 mg (Days 1', 'and 2)', 'and 2)', '12 mgb', '12 mgb', 'Day 8-14', '12 mg', '12 mg', '12 mg', '12 mg', '18 mg', '18 mg', 'Day 15-21', '18 mg', '18 mg', '18 mg', '18 mg', '24 mg', '24 mg', 'Day 22-28', '18 mg', '18 mg', '24 mg', '24 mg', '30 mg', '30 mg', 'Day 29-35', '24 mg', '18 mg', '30 mg', '24 mg', '36 mg', '36 mg', 'Day 36-42', '24 mg', '18 mg', '36 mg', '24 mg', '42 mg', '36 mg', 'Day 43-49', '30 mg', '18 mg', '42 mg', '24 mg', '48 mg', '36 mg', 'a', 'Administration of a given dose will take place throughout the days indicated. The new dose starts the morning', 'after the telephone contact or the morning after the clinic visit (ie, Days 8, 15, 22, 29, 36, and 43), as applicable.', 'b', 'Patients will receive 6 mg on days 1 and 2, and 12 mg starting on day 3.', '14']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'bid=twice a day; CYP=cytochrome P450; IMP=investigational medicinal product.', 'Note: CYP impaired=patients who are receiving a strong CYP2D6 inhibitor or who are a CYP2D6 poor', 'metabolizer. The investigator, in consultation with the patient and caregiver/adult, will determine if a dose increase', 'is warranted to achieve optimal tic reduction.', 'IMP: TEV-50717', 'Reference Therapy: Placebo', 'Duration of Patient Participation: This study will consist of up to a 31-day screening period, a 12-week', 'double-blind treatment period, and a 1-week washout period. Patients who complete the study may be eligible to', 'begin participation in an open-label safety extension study TV50717-CNS-30047 after the end of the washout', 'period. Patients not participating in Study TV50717-CNS-3004 will have a follow-up telephone contact to evaluate', 'safety 1 week after the end of the washout period (2 weeks after their last dose of IMP). Patients are expected to', 'participate in this study for its entire duration, which is a minimum of 14 weeks.', 'Inclusion Criteria: Patients may be enrolled in the study if they meet all of the following criteria:', 'a.', 'Patient is 6 to 16 years of age, inclusive, at baseline.', 'b.', 'Patient weighs at least 44 pounds (20 kg) at baseline.', 'c.', 'Patient meets the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-VTM)', 'diagnostic criteria for TS and, in the opinion of the investigator, patient, and caregiver/adult, the', \"patient's active tics are causing distress or impairment.\", 'd.', 'Patient has a TTS of 20 or higher on the YGTSS at screening and baseline.', 'e.', 'Patient is able to swallow study medication whole.', 'f.', 'Patient and caregiver/adult are willing to adhere to the medication regimen and to comply with all', 'study procedures.', 'g. Patient is in good general health, as indicated by medical and psychiatric history as well as physical', 'and neurological examination.', 'h.', \"In the investigator's opinion, the patient and caregiver/adult have the ability to understand the nature of\", 'the study and its procedures, and the patient is expected to complete the study as designed.', 'i.', \"Patient and caregiver/adult provide written informed consent/assent, depending on the child's age, as\", 'appropriate, according to local regulations.', 'j.', 'Females who are postmenarchal or >12 years of age may be included only if they have a negative', 'beta-human chorionic gonadotropin (B-HCG) test at baseline or are sterile. Definitions of sterile are', 'given in Appendix L.', 'k.', 'Females who are postmenarchal or >12 years of age whose male partners are potentially fertile (ie, no', 'vasectomy) must use highly effective birth control methods for the duration of the study (ie, starting at', 'screening) and for 30 days or 5 half-lives, whichever is longer after last dose of IMP. Further details', 'are included in Appendix L.', 'Exclusion Criteria: Patients will not be enrolled in this study if they meet any of the following criteria:', 'a.', 'Patient has a neurologic disorder other than TS that could obscure the evaluation of tics.', 'b.', \"The patient's predominant movement disorder is stereotypy (coordinated movements that repeat\", 'continually and identically) associated with autism spectrum disorder.', '15']\n\n###\n\n", "completion": "END"}